Vancouver, British Columbia TheNewswire – July 4, 2022. Lexston Life Sciences Corp. (the “Company”) (CSE:LEXT) (OTC:LEXTF) announces that further to its news releases dated June 1, 2022 and June 27, 2022, the Company has issued 18,562,440 units (“Units”) at a purchase price of $0.05 per Unit for gross proceeds of $928,122 (the “Private Placement”). Each Unit consists of one common share in the capital of the Company (“Share”) and one share purchase warrant (“Warrant”). Each full Warrant entitles the holder to purchase one Share for a period of five years, at a purchase price of $0.075 per Share.
The Company has paid $4,480 cash to Haywood Securities Inc and $15,400 to Raymond James Ltd. and issued 89,600 broker’s warrants to Haywood Securities Inc. and 308,000 broker’s warrants to Raymond James Ltd. as finders’ fees. The finders’ warrants are subject to the same terms and conditions as the Warrants issued pursuant to the Private Placement.
All securities issued pursuant to the Private Placement are subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.
The net proceeds from the Private Placement will be used by the Company for general working capital.
On Behalf of the Board of Directors
LEXSTON LIFE SCIENCES CORP.
Jagdip Bal Chief Executive Officer
Telephone: (604) 928-8913
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
Vancouver, British Columbia – TheNewswire – June 27, 2022. Lexston Life Sciences Corp. (the “Company”) (CSE:LEXT) (OTC:LEXTF) announces an increase to the non-brokered private placement announced on June 1, 2022. The Private Placement has been increased to up to 22,000,000 units (the “Units”) at a purchase price of $0.05 per Unit to raise gross proceeds of up to $1,100,000 (the “Private Placement”). Each unit will consist of one common share in the capital of the Company and one share purchase warrant (a “Warrant”). Each full warrant will entitle the holder to purchase one additional common share in the capital of the Company for a period of five years, at a purchase price of $0.075 per Share.
The Company may pay a finder’s fee in connection with the Private Placement within the maximum amount permitted by the policies of the Canadian Securities Exchange (the “Exchange”) and the applicable securities laws. Certain directors, officers and insiders of the Company may participate in the Private Placement. The Private Placement is subject to several conditions, including receipt of all necessary corporate and regulatory approvals, including the Exchange. All securities to be issued in connection with the Private Placement will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.
The net proceeds from the Private Placement will be used by the Company for general working capital.
No new insiders or control persons will be created as a result of this Private Placement.
On Behalf of the Board of Directors
LEXSTON LIFE SCIENCES CORP.
Jagdip Bal Chief Executive Officer
Telephone: (604) 928-8913
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
Vancouver, British Columbia, June 9, 2022. Lexston Life Sciences Corp. (the “Company”) (CSE: LEXT) (OTCQB: LEXTF) announces that its subsidiaries Egret Bioscience Ltd. and Zenalytic Laboratories Ltd. (the “Subsidiaries”) will be laying off all their employees effective June 15, 2022. The decision was made due to the lack of profitability and to save costs. Some scientific staff will be available on as needed basis. The Company is planning the future for the Subsidiaries.
On Behalf of the Board of Directors
LEXSTON LIFE SCIENCES CORP. Jagdip Bal Chief Executive Officer Telephone: (604) 928-8913
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
Vancouver, British Columbia, June 3, 2022. Lexston Life Sciences Corp. (the “Company”) (CSE: LEXT) (OTCQB: LEXTF) announces that it has cancelled an aggregate of 796,000 incentive stock options (the “Cancelled Options”) previously held by certain directors, officers, employees, and consultants of the6 Company. The Cancelled Options were comprised of the following:
Number of CancelledOptions
Original Date of Grant
Expiry Date
Exercise Price
400,000
January 18, 2021
January 18, 2026
$0.50
340,000
July 5, 2021
July 5, 2026
$0.875
56,000
September 8, 2021
September 8, 2026
$0.90
On Behalf of the Board of Directors LEXSTON LIFE SCIENCES CORP. Jagdip Bal Chief Executive Officer Telephone: (604) 928-8913 The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
Vancouver, British Columbia, June 1, 2022. Lexston Life Sciences Corp. (the “Company”) (CSE: LEXT) (OTCQB: LEXTF) announces a non-brokered private placement consisting of up to 15,000,000 units (the “Units”) at a purchase price of $0.05 per Unit to raise gross proceeds of up to $750,000 (the “Private Placement”). Each unit will consist of one common share in the capital of the Company and one share purchase warrant (a “Warrant”). Each full warrant will entitle the holder to purchase one additional common share in the capital of the Company for a period of five years, at a purchase price of $0.075 per Share.
The Company may pay a finder’s fee in connection with the Private Placement within the maximum amount permitted by the policies of the Canadian Securities Exchange (the “Exchange”) and the applicable securities laws. Certain directors, officers and insiders of the Company may participate in the Private Placement. The Private Placement is subject to several conditions, including receipt of all necessary corporate and regulatory approvals, including the Exchange. All securities to be issued in connection with the Private Placement will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.
The net proceeds from the Private Placement will be used by the Company for general working capital.
On Behalf of the Board of Directors LEXSTON LIFE SCIENCES CORP. Jagdip Bal Chief Executive Officer Telephone: (604) 928-8913
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
Vancouver, British Columbia, April 11, 2022. Lexston Life Sciences Corp. (the “Company” or “Lexston”)(CSE: LEXT) (OTCQB: LEXTF) a biotechnology company focused on the development of analytical services and production of botanically derived psychedelics, is pleased to announce that, on April 4, 2022, its wholly-owned subsidiary, Egret Bioscience Ltd., sponsored the whole genome sequencing, open access archiving and biobanking of the Pacific Northwest wood-rotting psychedelic mushroom, Psilocybe allenii.
The “Allenii project” is a joint effort with the Entheome Foundation to sequence this species of psychedelic mushroom which was identified by modern science less than a decade ago in the Pacific Northwest (https://www.cabdirect.org/cabdirect/abstract/20133089027). Psilocybe allenii is found on the Pacific Northwest Coast ranging from northern California to British Columbia. It shares many morphological characteristics with other Psilocybe species, in particular P. cyanescens, and has the particularity of having a convex to plane cap that lacks the wavy margins of P. cyanescens (also known as “wavy caps”). The species is thought to contain both psilocybin and psilocin in concentrations of less than 1%.
“In addition to making the data open access for others to study, our team intends to utilize the sequence information to resolve the relationship with other Psilocybe mushrooms as well as to understand the biosynthetic differences between Psilocybe mushroom species and their chemical constituents. We have a particular interest in the expression of aeruginascin and bufotenine, minor tryptamines potentially involved in wood-lovers paralysis (WLP), an understudied phenomenon that has led some regulators to establish restrictions to the access of species other than P. cubensis.” Stated Philippe Henry PhD, Director and Chief Science Officer of Lexston.
Psilocybe allenii. USA, CA, Oakland, 5 January 2006. Peter G. Werner.
About the Entheome Foundation
The Entheogen Genome Project is an initiative partaken by the Entheome Foundation with the mission to preserve and understand all entheogenic flora, fauna and funga. As part of this endeavor, the Entheome Foundation collaborates with sponsors who provide the monetary resources for the procurement, genomic sequencing and biobanking of specific specimens, with the intention to make the information publicly accessible. The Entheome Foundation is an open-science platform for psychedelics research. www.entheome.org
Lexston Life Sciences Corp. (“Lexston”) is a Canadian biotechnology company providing cannabis testing and research services. Lexston is also in the process of securing licensing under the exemptions prescribed by section 56 of the Controlled Drugs and Substances Act (Canada) to enable the expansion of prescribed by section 56 of the Controlled Drugs and Substances Act (Canada) to enable the expansion of psychedelic molecules in the lab and point of care. Lexston intends to develop and validate methods for standardized manufacturing of plant derived psychedelics in support of burgeoning trials in the field of mental health and wellness.
On Behalf of the Board of Directors
LEXSTON LIFE SCIENCES CORP.
Jagdip Bal Chief Executive Officer Telephone: (604) 928-8913
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
929 Mainland Street Vancouver, BC V6B 1S3
Phone: (604) 928-8913
Fax: (604) 628-0129
Email: admin@lexston.net
Website: www.lexston.ca
Forward-Looking Statements
This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of LEXT to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release.
Risks, uncertainties, and other factors involved with forward-looking information could cause actual events, results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
Vancouver, British Columbia, March 25, 2022. Lexston Life Sciences Corp. (CSE: LEXT) (the “Company” or “Lexston”) announces the resignation of Dimitrios Mitrakos as the Chief Financial Officer and Corporate Secretary of the Company and the appointment of Company’s director Jatinder Jesse Manhas as the Chief Financial Officer and Corporate Secretary of the Company.
The Company also announces the appointment of director Graeme Staley to the audit committee of the Company. The audit committee of the Company now consists of directors Jagdip Singh Bal, Harinder Bains and Graeme Staley.
The Company thanks Mr. Mitrakos for his service as the Chief Financial Officer and Corporate Secretary.
On Behalf of the Board of Directors
LEXSTON LIFE SCIENCES CORP.
Jagdip Bal Chief Executive Officer Telephone: (604) 928-8913
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
929 Mainland Street Vancouver, BC V6B 1S3
Phone: (604) 928-8913
Fax: (604) 628-0129
Email: admin@lexston.net
Website: www.lexston.ca
Forward-Looking Statements
This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of LEXT to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release.
Risks, uncertainties, and other factors involved with forward-looking information could cause actual events, results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
Lexston Life Sciences (LEXT) received a Section 56 exemption to research psilocybin. It is developing a tool that can rapidly identify and quantify different mushroom compounds such as psilocin, psilocybin, baeocystin, norbaeocystin and aeruginascin.
Vancouver, British Columbia, January 24, 2022. Lexston Life Sciences Corp. (the “Company” or “Lexston”) (CSE: LEXT) (OTCQB: LEXTF) is pleased to announce that the Company’s wholly owned subsidiary, Egret Bioscience Ltd. (“Egret”) has developed and validated a targeted genetic barcode consisting of eight Single Nucleotide Polymorphism (“SNP”) for psychedelic mushroom genetic identification (“Egret Psilocybe Assay”). Egret has previously developed and published similar genetic identification tests for the Cannabis Industry (https://t.co/rh1VJ5cf0a) and have been offering this service to licensed producers through its affiliated licensed lab, Zenalytic Laboratories Ltd. In early January, the Controlled Substances Directorate of Health Canada amended their regulations to allow practitioners to prescribe restricted drugs, such as psilocybin and psilocin through the Special Access Program (“SAP”) for patient with treatment resistant depression and other debilitating illnesses that have failed to respond to conventional treatments. As with other restricted drugs, Health Canada has mandated a stringent quality control and compliance routine testing for every batch destined for the SAP. One of the key requirements put in place by the regulator is the requirement for a genetic identity test. “Our team has been steadfast at work to develop and implement validated state-of-the-art methods for genetic identification of psychedelic mushrooms. Our assay provides the first of its kind Psilocybe genetic barcode, a rapid and efficient diagnostic test able to provide individual genetic strain identification and differentiate strains from the main groups of Psilocybe mushrooms, in particular P. cubensis, P. tampanensis and P. mexicana (P. galindoi). This traceability and authentication tool will be paramount in establishing best practice for the psychedelic industry.” Stated Jag Bal, CEO and Director of Lexston.
Phylogenetic tree showing the relationship between 84 psychedelic mushroom samples from which the Egret genetic barcode was developed. Reproduced from data made available by McKernan and colleagues (2021; https://doi.org/10.12688/f1000research.55301.2). Of particular note, the more potent P. cubensis accessions such as P. Envy cluster closely to the P. azurescens, P. tampanensis and P. mexicana accessions.
Lexston Life Sciences Corp. (“Lexston”) is a Canadian biotechnology company providing cannabis testing and research services. Lexston is also in the process of securing licensing under the exemptions prescribed by section 56 of the Controlled Drugs and Substances Act (Canada) to enable the expansion of prescribed by section 56 of the Controlled Drugs and Substances Act (Canada) to enable the expansion of psychedelic molecules in the lab and point of care. Lexston intends to develop and validate methods for standardized manufacturing of plant derived psychedelics in support of burgeoning trials in the field of mental health and wellness.
On Behalf of the Board of Directors
LEXSTON LIFE SCIENCES CORP.
Jagdip Bal Chief Executive Officer Telephone: (604) 928-8913
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
929 Mainland Street Vancouver, BC V6B 1S3
Phone: (604) 928-8913
Fax: (604) 628-0129
Email: admin@lexston.net
Website: www.lexston.ca
Forward-Looking Statements
This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of LEXT to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release.
Risks, uncertainties, and other factors involved with forward-looking information could cause actual events, results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
Vancouver, British Columbia, January 19, 2022. Lexston Life Sciences Corp. (the “Company” or “Lexston”) (CSE: LEXT) (OTCQB: LEXTF) is pleased to announce that the company’s wholly owned subsidiary, Egret Bioscience Ltd. (“Egret”) has recently received funding from the Canadian government for their project on Cannabis transformation to develop new breeding techniques using CRISPR-Cas9 technology. The project, entitled “Screening of Egret’s hemp genotypes for proof of concept tissue culture and transformation method validation“ was initiated by the National Research Council of Canada (NRC) in July 2021 through their Industrial Research Assistance Program (NRC-IRAP). The Government contribution to the research totals over CAD$55,000. The goal of this year-long project is to develop new high essential oil hemp genotypes by manipulating the Cannabis sativa L. genome with the CRISPR gene editing system at targets identified by Egret scientists. On September 30, 2021, the NRC provided a project report for the initial stages of transformation of Cannabis tissue cultures. The team reported successfully creating cannabis protoplasts (cannabis cell cultures without cell walls) from four of Egret’s flagship essential oil hemp varieties: Hempress, Autopilot, Abacus and Suver Haze. The team also successfully transformed the protoplast with a marker protein, Green Fluorescent Protein (GFP) to validate the methods developed thus far.
Successfully transfected hemp protoplasts expressing Green Fluorescent Protein.
“We are tremendously excited to see the progress made by NRC Scientists, lead by Dr. Pankaj Bhowmik on four of the five varieties of essential oil hemp that we recently imported from the United States. Our high CBD, high essential oil content germplasm will be transformed into zero THC versions to ensure their compliance with the Canadian Industrial Hemp Regulations and the specification of the international hemp markets which requires hemp flowers to test below 0.3% total THC”, stated Philippe Henry PhD, Chief Science Officer and Director of Lexston. Lexston intends to leverage the methods developed through this initial research for future technology transfers into other species of interest to the company’s psychedelic pipeline.
Lexston Life Sciences Corp. (“Lexston”) is a Canadian biotechnology company providing cannabis testing and research services. Lexston is also in the process of securing licensing under the exemptions prescribed by section 56 of the Controlled Drugs and Substances Act (Canada) to enable the expansion of prescribed by section 56 of the Controlled Drugs and Substances Act (Canada) to enable the expansion of psychedelic molecules in the lab and point of care. Lexston intends to develop and validate methods for standardized manufacturing of plant derived psychedelics in support of burgeoning trials in the field of mental health and wellness.
On Behalf of the Board of Directors
LEXSTON LIFE SCIENCES CORP.
Jagdip Bal Chief Executive Officer Telephone: (604) 928-8913
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
929 Mainland Street Vancouver, BC V6B 1S3
Phone: (604) 928-8913
Fax: (604) 628-0129
Email: admin@lexston.net
Website: www.lexston.ca
Forward-Looking Statements
This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of LEXT to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release.
Risks, uncertainties, and other factors involved with forward-looking information could cause actual events, results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
cookielawinfo-checkbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
